Again Acquires Genomatica, Boosting Biomanufacturing

In a significant move to consolidate advanced capabilities in the rapidly evolving biomanufacturing sector, Danish firm Again has acquired US-based industrial biotechnology pioneer Genomatica. This strategic union aims to fuse Genomatica's deep expertise in computational biology and bioprocess engineering with Again's proficiency in scaling biological production. While financial specifics remain undisclosed, the transaction is set to create a formidable entity capable of navigating the entire biomanufacturing value chain, from initial molecular design to industrial-scale output.

Genomatica, founded in 1998, brings to the table over two decades of proprietary data and a robust intellectual property portfolio, including more than 1,100 patents. The company has a proven track record in developing biological processes for producing chemicals and materials, collaborating with major manufacturers and consumer goods companies. Its strength lies in its advanced computational tools for pathway discovery and strain design, underpinned by sophisticated machine-learning analytics.

Again, a Copenhagen-headquartered company, leverages artificial intelligence, computational modeling, and engineering to optimize and scale biomanufacturing processes across diverse feedstocks. Operating in sectors such as industrial, personal care, home care, and food, Again has established a presence in key innovation hubs including Copenhagen, Munich, and Houston. The integration of Genomatica's technology is expected to dramatically accelerate Again's mission to develop feedstock-independent and highly efficient biological production pathways.

The combined entity will possess an end-to-end platform, encompassing pathway discovery, biological design, process development, and large-scale manufacturing. This comprehensive offering addresses a critical market need, particularly as governments in the US and Europe increasingly prioritize bolstering domestic biomanufacturing capacity and enhancing supply chain resilience. Initiatives like the BIOSECURE Act and substantial federal funding for bio-infrastructure underscore this strategic imperative.

Max Kufner, CEO of Again, highlighted the synergistic potential, stating, “AI is transforming biology, but its true value is realized through commercial-scale execution. Genomatica’s pioneering work in AI and computational biotechnology for molecule design, when combined with our scale-up platform and novel feedstock technologies, positions us to build the world’s premier biomanufacturing platform. This will unlock novel products and supply chains essential for numerous industries.”

This acquisition is particularly noteworthy given the increasing demand for sustainable and domestically produced chemicals and materials. The biomanufacturing market, projected to grow significantly in the coming years, is driven by a push for greener alternatives to petrochemicals. By integrating Genomatica's extensive data and AI capabilities with its own scaling expertise, Again is well-positioned to capture a larger share of this expanding market, offering a diversified business model that includes technology licensing, co-development, and direct product sales.